Study: smartwatches like Apple Watch and Fitbit, which can measure heart rate variability, could help detect COVID-19 at least a week before symptoms appear
Smartwatches and other wearable devices that continuously measure users' heart rates, skin temperature and other physiological markers …
Context & Ripple Effects
This study lands mid-arc in the wearables-as-medical-sensors story. Back in July 2020, the framing was prospective — sensors gathering temperature, heart rate, and blood oxygen 'may become' personal warning systems (wearables as COVID warning systems). By November, devices were already deployed in sports leagues, factories, nursing homes, and colleges (early institutional adopters). What changes with this research is the claim's strength: detection is no longer just contemporaneous tracking but pre-symptomatic, at least a week ahead.
The lineage runs through Apple's earlier health-detection bets — the Stanford and American Well heart-condition studies and the UCSF–Cardiogram DeepHeart results on hypertension and sleep apnea — which established that consumer-grade optical heart sensors could carry clinical signal. The UW–Apple respiratory-illness partnership announced months later shows Apple treating COVID-era findings as a program, not a one-off.
First-order effects
- Apple and Fitbit get independent research validation that their existing hardware can flag infection before users feel sick — turning a passive fitness metric (heart rate variability) into an active screening feature with no new sensor required.
- For Fitbit specifically, which has struggled with low hardware margins and is headed for rebranding under Google Health, pre-symptomatic illness detection is a differentiator that shifts value from the device sale to the health data layer.
Second-order effects
- Institutions that already adopted COVID-detection wearables — the sports leagues, factories, nursing homes, and colleges covered in November — now have a business case for continuous rather than reactive screening, pulling procurement toward whichever platform validates best.
- Rival wearable makers face pressure to match physiological anomaly detection in software, since the study shows the capability depends on algorithms over existing sensors, not new silicon — compressing the hardware advantage gap.
Third-order effects
- The pattern points toward smartwatches functioning as de facto diagnostic devices before formal approval: the Apple Watch is not FDA-cleared for these applications, yet clinicians already use it that way, building a regulatory reckoning over how continuous-consumer-data medicine gets cleared.
- If each successive study extends the detectable-condition list — hypertension and sleep apnea in 2017, COVID here, pregnancy detection by 2025 — the structural endpoint is the wrist becoming a continuous screening platform, with platform owners controlling the health-data funnel.
The trend: Consumer smartwatches are accumulating study-by-study evidence of pre-symptomatic disease detection, converting fitness hardware into a clinically consequential early-warning layer that regulators have not yet caught up to.